{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:48:57Z","timestamp":1776422937714,"version":"3.51.2"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1097\/md.0000000000001156","type":"journal-article","created":{"date-parts":[[2015,9,23]],"date-time":"2015-09-23T22:21:00Z","timestamp":1443046860000},"page":"e1156","source":"Crossref","is-referenced-by-count":16,"title":["The Efficacy of Parathyroid Hormone Analogues in Combination With Bisphosphonates for the Treatment of Osteoporosis"],"prefix":"10.1097","volume":"94","author":[{"given":"Wan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210226","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMcp043801","article-title":"Clinical practice. Postmenopausal osteoporosis","volume":"353","author":"Rosen","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-3-20210226","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00198-013-2422-6","article-title":"Epidemiology of fractures in Iceland and secular trends in major osteoporotic fractures 1989\u20132008","volume":"25","author":"Siggeirsdottir","year":"2014","journal-title":"Osteoporos Int"},{"key":"R3-3-20210226","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","article-title":"Epidemiology and outcomes of osteoporotic fractures","volume":"359","author":"Cummings","year":"2002","journal-title":"Lancet"},{"key":"R4-3-20210226","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025","volume":"22","author":"Burge","year":"2007","journal-title":"J Bone Miner Res"},{"key":"R5-3-20210226","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","article-title":"Treatment of postmenopausal osteoporosis","volume":"359","author":"Delmas","year":"2002","journal-title":"Lancet"},{"key":"R6-3-20210226","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00198-014-2684-7","article-title":"External auditory canal and middle ear cholesteatoma and osteonecrosis in bisphosphonate-treated osteoporosis patients: a Danish national register-based cohort study and literature review","volume":"25","author":"Thorsteinsson","year":"2014","journal-title":"Osteoporos Int"},{"key":"R7-3-20210226","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00198-004-1806-z","article-title":"Timing of follow-up densitometry in hormone replacement therapy users for optimal osteoporosis prevention","volume":"16","author":"Checa","year":"2005","journal-title":"Osteoporos Int"},{"key":"R8-3-20210226","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.maturitas.2011.11.018","article-title":"An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis","volume":"71","author":"Komm","year":"2012","journal-title":"Maturitas"},{"key":"R9-3-20210226","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1210\/er.2001-6002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"key":"R10-3-20210226","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1001\/jama.293.18.2257","article-title":"Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials","volume":"293","author":"Bischoff-Ferrari","year":"2005","journal-title":"JAMA"},{"key":"R11-3-20210226","doi-asserted-by":"crossref","first-page":"e26267","DOI":"10.1371\/journal.pone.0026267","article-title":"Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials","volume":"6","author":"Shen","year":"2011","journal-title":"Plos One"},{"key":"R12-3-20210226","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s00198-010-1460-6","article-title":"The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial","volume":"22","author":"Quesada-Gomez","year":"2011","journal-title":"Osteoporos Int"},{"key":"R13-3-20210226","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R14-3-20210226","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-3-20210226","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12020-012-9819-4","article-title":"Combination therapy with risedronate and teriparatide in male osteoporosis","volume":"44","author":"Walker","year":"2013","journal-title":"Endocrine"},{"key":"R16-3-20210226","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"key":"R17-3-20210226","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"R18-3-20210226","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","author":"Cosman","year":"2005","journal-title":"N Engl J Med"},{"key":"R19-3-20210226","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"R20-3-20210226","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R22-3-20210226","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"R23-3-20210226","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1359\/jbmr.080805","article-title":"Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans","volume":"23","author":"Keaveny","year":"2008","journal-title":"J Bone Miner Res"},{"key":"R24-3-20210226","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bone.2013.09.008","article-title":"Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002\u20132012","volume":"57","author":"Wysowski","year":"2013","journal-title":"Bone"},{"key":"R25-3-20210226","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semarthrit.2010.06.001","article-title":"The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis","volume":"40","author":"Jansen","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"R26-3-20210226","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","article-title":"Mechanisms of anabolic therapies for osteoporosis","volume":"357","author":"Canalis","year":"2007","journal-title":"N Engl J Med"},{"key":"R27-3-20210226","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrendo.2011.108","article-title":"Parathyroid hormone analogues in the treatment of osteoporosis","volume":"7","author":"Kraenzlin","year":"2011","journal-title":"Nat Rev Endocrinol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000001156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:46:50Z","timestamp":1620960410000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201509040-00003"}},"subtitle":["A Meta-Analysis of Randomized Controlled Trials"],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":26,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000001156","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}